Everything below concerns Metabolite. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Cannabinol (CBN) is a mildly psychoactive cannabinoid acting as a low-affinity partial agonist at CB1 and CB2 receptors. CBN interacts with other neurotransmitter systems (e.g., dopaminergic, serotonergic), requiring higher doses for physiologic effects like mild sedation compared to THC. Isolated in the late 1800s, its structure was elucidated in the 1930s, and chemical synthesis was achieved by 1940. Recent studies indicate that CBN exhibits antiproliferative effects against glioma, liver, and breast cancer cell lines by triggering cell cycle arrest at G1 or S-Phase. In estrogen receptor-positive breast cancer models, CBN was found to be the most effective in suppressing the new synthesis of aromatase, the enzyme responsible for estrogen production that fuels tumor growth, when compared to THC and CBD.
There are about 18,000 U.S. police agencies from local to national level in the United States. Law in the United States is mainly enforced by local police departments and sheriff departments in their municipal or county jurisdictions. The state police departments have authority in their respective state, and federal agencies such as the Federal Bureau of Investigation (FBI) and the U.S. Marshals Service have national jurisdiction and specialized duties, such as protecting civil rights, national security, enforcing U.S. federal courts' rulings and federal laws, and interstate criminal activity. State courts conduct almost all civil and criminal trials, while federal courts adjudicate the much smaller number of civil and criminal cases that relate to federal law. There is no unified "criminal justice system" in the United States. The American prison system is largely heterogenous, with thousands of relatively independent systems operating across federal, state, local, and tribal levels. In 2026, "these systems hold nearly 2 million people in 1,566 state prisons, 98 federal prisons, 3,116 local jails, 1,277 juvenile correctional facilities, 220 immigration detention facilities, and 77 Indian country jails, as well as in military prisons, civil commitment centers, state psychiatric hospitals, and prisons in the U.S. territories—at a system-wide cost of at least $445 billion each year." Despite disparate systems of confinement, four main institutions dominate: federal prisons, state prisons, local jails, and juvenile correctional facilities.
Health technology is defined by the World Health Organization as the "application of organized knowledge and skills in the form of devices, medicines, vaccines, procedures, and systems developed to solve a health problem and improve quality of lives". This includes pharmaceuticals, devices, procedures, and organizational systems used in the healthcare industry, as well as computer-supported information systems. In the United States, these technologies involve standardized physical objects, as well as traditional and designed social means and methods to treat or care for patients.
Sources: en.wikipedia.org
== Regulations for pet food ingredients == Aside from the CFIA, which makes the use of specified risk materials illegal, pet food ingredients do not need to be approved by any regulatory body in Canada. However, if manufacturers plan to expand into the U.S. market, they must adhere to regulations imposed by each state, or comply with guidelines established by the American Association of Feed Control Officials (AAFCO). These guidelines will provide country-wide acceptable ingredients, and nutritional recommendations based on research collected by the National Research Council (NRC). As of August 2021, AAFCO has approved the use of Black Soldier Fly (BSF) insects in pet food - specifically for adult dogs. The use of insects in feed in the European Union was previously prohibited under an act called "TSE Regulation" (Article 7 and Annex IV of Regulation 999/2001) that bans the use of animal protein in animal feed. In July 2017 this regulation was revised and partially lifts the ban on animal proteins, allowing insects to be included in fish feed. This was coupled with another change that reclassified insects in the European Union (EU) catalogue of feed materials. This change specifically refers to fats and proteins from insects instead of classifying them under a broad title of animal products. Due to this change, producers now must list the species and life stage of the insect on their product. Novel pet food ingredients in Europe must also follow certain stringent regulations, making approval of new ingredients a lengthy process.
As of November 2022, Domino's Pizza opened in Montevideo, Uruguay, being the franchise's first location in the Southern Cone, and announcing the plan of opening 20 stores in this city in the next five years. In Central Asia, Domino's Pizza opened its first franchise in May 2024 in Tashkent (Uzbekistan).
=== Wealth and assets === Morea has been listed in various publications among Indian film personalities with significant net worth. As of 2025, his net worth has been estimated at over US$150 million by some sources. He is reported to own several high-end vehicles, including models such as the Rolls Royce Ghost, BMW M8, Lamborghini Sián, Mercedes GLS, Porsche 911, Ford Endeavour, as well as motorcycles like the Harley-Davidson Forty-Eight, Royal Enfield Bullet 500, and Aprilia RSV4. Reports also indicate that he owns multiple residential properties in India and abroad.
Only a year after Röntgen's discovery of X-rays, the American engineer Wolfram Fuchs (1896) gave what is probably the first protection advice, but it was not until 1925 that the first International Congress of Radiology (ICR) was held and considered establishing international protection standards. The effects of radiation on genes, including the effect of cancer risk, were recognized much later. In 1927, Hermann Joseph Muller published research showing genetic effects and, in 1946, was awarded the Nobel Prize in Physiology or Medicine for his findings. The second ICR was held in Stockholm in 1928 and proposed the adoption of the röntgen unit, and the International X-ray and Radium Protection Committee (IXRPC) was formed. Rolf Sievert was named chairman, but a driving force was George Kaye of the British National Physical Laboratory. The committee met in 1931, 1934, and 1937. After World War II, the increased range and quantity of radioactive substances being handled as a result of military and civil nuclear programs led to large groups of occupational workers and the public being potentially exposed to harmful levels of ionising radiation. This was considered at the first post-war ICR convened in London in 1950, when the present International Commission on Radiological Protection (ICRP) was born. Since then the ICRP has developed the present international system of radiation protection, covering all aspects of radiation hazards.
Sources: en.wikipedia.org
=== Buses === Bromley is served by London Buses routes 61, 119, 126, 138, 146, 162, 208, 227, 246, 261, 269, 314, 320, 336, 352, 354, 358, 367, 638, N3, N199, SL3 and SL5. These connect it with areas including Beckenham, Bexley, Bexleyheath, Biggin Hill, Catford, Chislehurst, Croydon, Crystal Palace, Downham, Elmers End, Eltham, Grove Park, Hayes, Lee Green, Lewisham, Locksbottom, Mottingham, New Addington, Orpington, Penge, Petts Wood, Sidcup, West Wickham & Westerham.
Pyrite oxidation by atmospheric O2 in the presence of moisture (H2O) initially produces ferrous ions (Fe2+) and sulfuric acid which dissociates into sulfate ions and protons, leading to acid mine drainage (AMD). An example of acid rock drainage caused by pyrite is the 2015 Gold King Mine waste water spill.
=== Travel distances === Teams participating in the 2026 World Cup had to travel an average of 5,146 total miles (8,281.7 km) between venues during the tournament. For the 2014 tournament in Brazil, the average distance was 7,054 miles (11,352.2 km), while teams playing in the 2018 tournament in Russia traveled an average of 5,441 miles (8,756.4 km).
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.